Latest Industry Insights

In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to find out more about the company’s mission, its science and its vision for the future of neuroscience drug development.

In this interview, Felix Spira, senior manager at Molecular Devices, discusses how automation and AI improve brain organoid cultivation, enabling consistent long-term models that advance research into complex neurodegenerative diseases.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

Discover how scalable, human-based in vitro models are reshaping discovery pipelines, balancing complexity with reproducibility, and enabling new kinds of experimentation that go beyond the limits of animal research.

Technology Networks spoke with Nautilus Biotechnology and the Allen Institute about their new agreement to advance Alzheimer’s research through proteoform analysis.

This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.

In this article, discover how the FDA and NIH are replacing animal testing with human models, such as organoids, featuring expert insights on safer, faster and ethical drug development.

Stem cell therapy using iPSC technology on the surface of the eye could cure blindness by replacing damaged corneal cells – a new hope for vision restoration.

Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and scalable alternatives.

Joel Eichmann discusses the challenges of scaling adherent cell culture and the innovations helping to streamline the transition from discovery to GMP manufacturing.